Similarly, treatment of malaria infected mice with the PPAR-γ agonist rosiglitazone in combination with artesunate at the onset of neurological symptoms achieved higher plasma and brain levels of Ang1 and a lower Ang2:Ang1 ratio compared to mice treated with artesunate alone. This evidence concerns the gene ANGPT2 and malaria.